Summary
1.19 -0.01(-0.42%)10/04/2024
Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (ACRS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.42 | 1.28 | 1.28 | -2.07 | -3.66 | -80.32 | 4.87 | -89.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.19 | |
| Open | 1.20 | |
| High | 1.20 | |
| Low | 1.18 | |
| Volume | 150,681 | |
| Change | 0.01 | |
| Change % | 0.42 | |
| Avg Volume (20 Days) | 206,393 | |
| Volume/Avg Volume (20 Days) Ratio | 0.73 | |
| 52 Week Range | 0.59 - 6.25 | |
| Price vs 52 Week High | -81.04% | |
| Price vs 52 Week Low | 100.85% | |
| Range | -1.25 | |
| Gap Up/Down | 0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 84 | |
| EBIDTA | -134,348,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1300 | |
| WallStreet Target Price | 34.80 | |
| Book Value | 3.5370 | |
| Earnings Per Share | -1.5530 | |
| EPS Estimate Current Quarter | -0.2800 | |
| EPS Estimate Next Quarter | -0.3700 | |
| EPS Estimate Current Year | -1.6100 | |
| EPS Estimate Next Year | -1.6700 | |
| Diluted EPS (TTM) | -1.5530 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.5162 | |
| Return on asset (TTM) | -0.2171 | |
| Return on equity (TTM) | -0.6346 | |
| Revenue TTM | 6,840,000 | |
| Revenue per share TTM | 0.1310 | |
| Quarterly Revenue Growth (YOY) | 0.1450 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -27,989,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.7316 | |
| Revenue Enterprise Value | 89.3257 | |
| EBITDA Enterprise Value | 0.0478 | |
| Shares | ||
| Shares Outstanding | 61,227,300 | |
| Shares Float | 45,967,033 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 4.06 | |
| Institutions (%) | 93.54 | |
09/17 07:00 EST - globenewswire.com
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
09/10 07:00 EST - globenewswire.com
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York.
08/07 09:16 EST - zacks.com
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.42 per share a year ago.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.42 per share a year ago.
07/25 10:41 EST - zacks.com
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
07/23 08:45 EST - businesswire.com
AllClear Repair Services Approved as Honeywell Authorized Service Center
MIRAMAR, Fla.--(BUSINESS WIRE)-- #defenseaerospace--AllClear Repair Services (“ACRS”), a wholly owned subsidiary of AllClear Aerospace & Defense (“AllClear”), has been approved by Honeywell as an authorized service center for Honeywell military APUs and mechanical components for C-130, F-15, F-16, F-18 and military derivatives of B707 platforms. The Honeywell authorized service center agreement authorizes ACRS to perform maintenance on pneumatic components, starter control valves, anti-ice valves, wheels and b.
AllClear Repair Services Approved as Honeywell Authorized Service Center
MIRAMAR, Fla.--(BUSINESS WIRE)-- #defenseaerospace--AllClear Repair Services (“ACRS”), a wholly owned subsidiary of AllClear Aerospace & Defense (“AllClear”), has been approved by Honeywell as an authorized service center for Honeywell military APUs and mechanical components for C-130, F-15, F-16, F-18 and military derivatives of B707 platforms. The Honeywell authorized service center agreement authorizes ACRS to perform maintenance on pneumatic components, starter control valves, anti-ice valves, wheels and b.
07/16 16:01 EST - globenewswire.com
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT® (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT® (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans.
07/11 07:12 EST - marketbeat.com
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.
06/25 12:36 EST - globenewswire.com
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 billion in 2023. Looking forward, the 7MM are projected to reach US$ 33.8 billion by 2034, exhibiting a growth rate (CAGR) of 2.32% during 2023-2034.
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 billion in 2023. Looking forward, the 7MM are projected to reach US$ 33.8 billion by 2034, exhibiting a growth rate (CAGR) of 2.32% during 2023-2034.
06/06 07:00 EST - globenewswire.com
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris' website, www.aclaristx.com.
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris' website, www.aclaristx.com.
05/08 06:30 EST - businesswire.com
American Clinical Research Services Announces Strategic Acquisition of Elixia
RALEIGH, N.C.--(BUSINESS WIRE)--American Clinical Research Services Announces Strategic Acquisition of Elixia.
American Clinical Research Services Announces Strategic Acquisition of Elixia
RALEIGH, N.C.--(BUSINESS WIRE)--American Clinical Research Services Announces Strategic Acquisition of Elixia.
05/07 21:44 EST - seekingalpha.com
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. (NASDAQ:ACRS ) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Officer Joe Monahan - Chief Scientific Officer Wally Smith - Scientific & Business Development Consultant Conference Call Participants Roger Song - Jefferies Thomas Smith - Leerink Partners Corinne Jenkins - Goldman Sachs Julian Harrison - Big TIG Alex Thompson - Stifel Gavin Clark-Gartner - Evercore ISI Operator Good day, and thank you for standing by. Welcome to the Aclaris Therapeutics First Quarter 2024 Conference Call.
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. (NASDAQ:ACRS ) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Officer Joe Monahan - Chief Scientific Officer Wally Smith - Scientific & Business Development Consultant Conference Call Participants Roger Song - Jefferies Thomas Smith - Leerink Partners Corinne Jenkins - Goldman Sachs Julian Harrison - Big TIG Alex Thompson - Stifel Gavin Clark-Gartner - Evercore ISI Operator Good day, and thank you for standing by. Welcome to the Aclaris Therapeutics First Quarter 2024 Conference Call.
05/07 18:16 EST - zacks.com
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.42 per share a year ago.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.42 per share a year ago.
05/07 16:01 EST - globenewswire.com
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
04/23 08:00 EST - prnewswire.com
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
CAMBRIDGE, Mass. , April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D.
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
CAMBRIDGE, Mass. , April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D.
04/05 10:46 EST - zacks.com
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
03/20 10:41 EST - zacks.com
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
03/04 13:06 EST - zacks.com
Aclaris (ACRS) Upgraded to Buy: Here's Why
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris (ACRS) Upgraded to Buy: Here's Why
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
02/27 10:36 EST - zacks.com
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago.
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago.
02/27 07:00 EST - globenewswire.com
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.